摘要
CRISPR/Cas9基因编辑技术能有效解决嵌合抗原受体T细胞(CAR-T)疗法中T细胞来源不足的问题,并通过敲除T细胞活性抑制的相关基因,增强其肿瘤杀伤作用。此外,该技术还可用于构建具有双重靶向作用的T细胞,阻止肿瘤免疫逃逸,减少治疗后复发、耐药等情况的发生。相较于其他基因工程技术的复杂过程,CRISPR/Cas9具有便捷高效及多重基因组编辑的优点,对完善CAR-T治疗策略具有重要意义。
CRISPR/Cas9 gene editing technology can effectively solve the problem of insufficient source of T cells in chimerical antigen receptor-T(CAR-T)therapy and enhance their anti-tumor abilities by knocking out the genes related to the suppression of T cells activity.The technology can also be used to construct T cells with dual-targeting effect to stop tumor immune escape and inhibit recurrence and drug resistance development during chemotherapy.Compared with the other genetic engineering technologies that have complex processes,multiple genome editing by CRISPR/Cas9 is a technology of efficient and convenient to operate.So it is believed to be valuable and potential target molecules for CAR-T therapy.
作者
伍琦
王绍波
WU Qi;WANG Shaobo(PET/CT Center,the Affiliated Hospital of Kunming University of Science and Technology,the First People's Hospital of Yunnan Province,Kunming 650032,China)
出处
《基础医学与临床》
2023年第8期1313-1316,共4页
Basic and Clinical Medicine
基金
国家自然科学基金(81760306)
云南省卫生高层次人才(医学学科带头人)(D-2018011)
云南省“万人计划”青年拔尖人才项目(YNWR-QNBJ-2018-243)。
